CorMedix Plans SUSTOL Relaunch While Its Heron Outlook Builds In CINVANTI Sales Erosion

The pending injectable is excluded from 2027 guidance, and CorMedix retained $75 million of borrowing capacity for future deals.

Share
CorMedix Plans SUSTOL Relaunch While Its Heron Outlook Builds In CINVANTI Sales Erosion

CorMedix, which develops and sells medicines for life-threatening conditions, plans to relaunch SUSTOL while its outlook for the Heron Therapeutics portfolio allows for declining CINVANTI sales. Management outlined the strategy on Monday's acquisition call, included in an SEC filing Tuesday, as CorMedix pursues a purchase that would add four commercial medicines.

CINVANTI Competition Shapes The Forecast

CorMedix's 2027 outlook for the Heron products is $125 million to $150 million, against approximately $150 million of net product revenue over the trailing 12 months. Chairman and CEO Joseph Todisco said CINVANTI weakness is included: “there is some erosion that's baked into the bottom end of that range.”

The agreement follows a patent setback for Heron's largest product. Todisco distinguished Azurity's potential competitor from a generic: it would be a separately marketed branded medicine with its own reimbursement code. He said CorMedix had closely examined the litigation and did not consider an Azurity appeal victory inevitable.

SUSTOL and CINVANTI prevent nausea and vomiting associated with chemotherapy. Todisco said, “it is our intent to relaunch SUSTOL.”

A separate injectable covered by Heron's development agreement has an FDA approval application pending. Todisco sees a possibility of approval during its initial review in 2027, but CorMedix excludes that product from its guidance.

Pain Medicines Broaden The Hospital Business

The purchase would give CorMedix 12 commercial products, according to its investor presentation. Alongside the chemotherapy medicines, it would add ZYNRELEF for postoperative pain and APONVIE for postoperative nausea and vomiting.

CorMedix's largest sales contributor is DefenCath, a catheter lock solution used to reduce bloodstream infections in adults with kidney failure undergoing chronic hemodialysis. Its August 29, 2025, Melinta Therapeutics purchase added six infectious-disease products, including REZZAYO, MINOCIN IV and VABOMERE, plus cardiovascular medicine TOPROL-XL. That deal expanded its commercial reach across hospitals, infusion centers and dialysis clinics.

Todisco said sharing facilities does not necessarily mean sharing prescribers. He framed the overlap as an opportunity to spread infrastructure costs across more products, rather than an automatic lift to existing drug sales.

CorMedix plans to devote more resources to APONVIE and bring aboard Heron employees concentrated in ZYNRELEF. Todisco acknowledged that NOPAIN reimbursement expires at the end of 2027 and said management is exploring ZYNRELEF opportunities outside orthopedics. CorMedix also anticipates FDA action on REZZAYO's preventive-use application in the first quarter of 2027.

Cash, Shares And Performance Payments

Under Monday's Heron agreement, CorMedix agreed to pay $145 million in cash, subject to purchase-price adjustments, plus approximately 14.6 million shares. The share count is fixed rather than moving with CorMedix's stock price.

Heron could receive up to $55 million more tied to ZYNRELEF's 2028 sales: $25 million at $65 million of sales and another $30 million at $95 million. It would also receive a 5% royalty on combined annual sales above $25 million for CINVANTI, SUSTOL and covered development products in 2027, 2028 and 2029.

CorMedix plans to fund the cash payment with $70 million on hand and a $75 million closing draw from its $150 million Pharmakon facility. Another $75 million can be borrowed at its discretion through June 30, 2028, for future deals.

Management expects immediate gains to earnings and free cash flow upon closing, and preliminary annual operating savings of $45 million to $60 million by year-end 2027. It expects the purchase to close in the first quarter of 2027.

Thursday's earnings call is the next forum for questions on third-quarter results, DefenCath and its reimbursement add-on payments.

Sources

More on CorMedix

All CorMedix (CRMD) coverage →